Shares of Zur Rose Group AG (OTCMKTS:ZRSEF – Get Rating) have been given a consensus recommendation of “Hold” by the ten brokerages that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $72.40.
ZRSEF has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft upgraded Zur Rose Group from a “sell” rating to a “hold” rating in a report on Monday, February 6th. Citigroup raised Zur Rose Group from a “sell” rating to a “neutral” rating in a research report on Monday, February 6th. Finally, Jefferies Financial Group upgraded Zur Rose Group from a “hold” rating to a “buy” rating in a research note on Monday, February 6th.
Zur Rose Group Stock Performance
Shares of Zur Rose Group stock opened at $53.37 on Tuesday. The company’s 50-day moving average price is $35.48 and its two-hundred day moving average price is $36.26. Zur Rose Group has a 52 week low of $23.64 and a 52 week high of $185.00.
About Zur Rose Group
Zur Rose Group AG engages in the operation of an e-commerce pharmacy and the wholesale of medical and pharmaceutical products. It operates through the following geograpical segments: Switzerland, Germany, and Europe. The company was founded by Walter Oberhänsli on April 6, 1993 and is headquartered in Frauenfeld, Switzerland.
- Get a free copy of the StockNews.com research report on Zur Rose Group (ZRSEF)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Zur Rose Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zur Rose Group and related companies with MarketBeat.com's FREE daily email newsletter.